Deals Of The Week: Exelixis/BMS, Valeant/Dow, Novartis Option Fund/Ascent
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims
FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.
Phase III Data With Scar Therapy Still Distant, Renovo Draws A Suitor
Pivotal results not due until 2011 – and skin peel drug needs a makeover.
Dermatology Space Waits For Skinny On Stiefel Buyout
Pure dermatology plays abound, but few are big enough to take on privately held Stiefel; where the company will find a fit is anybody’s guess.